Evidence map›Paper›PMID 38223524›Full record

Observational studyJournal of diabetes research2024

Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study.

Tomohiko Kimura, Masato Kubo, Kaio Takahashi, Ryo Wamata, Yuichiro Iwamoto, Hideyuki Iwamoto, Yukino Katakura, Junpei Sanada, Yoshiro Fushimi, Masashi Shimoda and 5 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of diabetes research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Tomohiko KimuraDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.ORCID https://orcid.org/0000-0003-3986-9494
Masato KuboDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Kaio TakahashiDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Ryo WamataDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Yuichiro IwamotoDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Hideyuki IwamotoDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Yukino KatakuraDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Junpei SanadaDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Yoshiro FushimiDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Masashi ShimodaDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Fuminori TatsumiDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Shuhei NakanishiDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Tomoatsu MuneDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Kohei KakuDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Hideaki KanetoDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, Japan.
Kawasaki Medical School · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, the development of once-weekly incretin-based injections dulaglutide and semaglutide has drawn a great deal of attention. This study is aimed at comparing the efficacy of once-weekly GLP-1 receptor activator (GLP-1RA) dulaglutide and semaglutide on glycemic control and several metabolic parameters in patients with type 2 diabetes mellitus. We compared various clinical parameters between before and after switching from dulaglutide to semaglutide in "study 1" (pre-post comparison) and set the control group using propensity score matching method in "study 2." In "study 1," six months after the switching, HbA1c was significantly reduced from 8.2% to 7.6% and body mass index was also decreased from 30.4 kg/m

Indexed as

Diabetes Mellitus, Type 2Immunoglobulin Fc FragmentsRecombinant Fusion ProteinsBody WeightGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesGlycemic ControlHumansHypoglycemic AgentsObesitySemaglutidedulaglutideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsSemaglutide

Identifiers

PMID38223524
PMCPMC10783983
OpenAlexW4390600128

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.